Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.

Takuro Goto, Eiji Kashiwagi, Guiyang Jiang, Yujiro Nagata, Yuki Teramoto, Alexander S. Baras, Shinichi Yamashita, Akihiro Ito, Yoichi Arai, Hiroshi MiyamotoPubMed 2020

TL;DR

This study reveals that estrogen receptor-beta (ERβ) signaling promotes cisplatin resistance in bladder cancer, particularly in female patients. Targeting ERβ with anti-estrogen therapies could be a promising strategy to enhance chemotherapy efficacy and overcome resistance.

What Problem Does This Paper Address?

Cisplatin-based chemotherapy is a cornerstone treatment for advanced bladder cancer, but its effectiveness is often hampered by the development of drug resistance. Understanding the molecular mechanisms behind this resistance is crucial for developing strategies to improve patient outcomes. Previous research by the authors hinted at the involvement of prostaglandin receptors and COX-2 in resistance. This paper delves into the role of estrogen receptor-beta (ERβ), a known player in urothelial cancer progression, and investigates its specific contribution to cisplatin resistance.

Methods

The researchers employed a multi-pronged approach:

  • Immunohistochemistry: They analyzed ERβ expression in tumor samples from 55 patients who received neoadjuvant cisplatin-based chemotherapy. This allowed them to correlate ERβ levels with treatment response.
  • Cell Line Studies: Human bladder cancer cell lines (UMUC3, 647V, and 5637) were used to investigate ERβ's direct impact on cisplatin sensitivity.
  • ERβ Knockdown: Short hairpin RNA (shRNA) was used to reduce ERβ expression, and the cells' sensitivity to cisplatin was then assessed.
  • ER Modulators: The effects of tamoxifen (an ER antagonist) and 17β-estradiol (E2, an ER agonist) on cisplatin sensitivity were evaluated.
  • CDDP-Resistant Cell Lines: Cell lines were engineered to be resistant to cisplatin through prolonged exposure, and their ERβ expression and sensitivity were analyzed.
  • Western Blotting: This technique was used to quantify the protein levels of ERβ and β-catenin in different cell line conditions.
  • MTT Assay: This standard assay was used to measure cell viability and determine drug cytotoxicity (IC50 values).
  • Reporter Gene Assay: This assay was employed to assess the activity of the Wnt/β-catenin signaling pathway.

Datasets

The study utilized:

  • Patient Tissue Samples: Immunohistochemistry was performed on muscle-invasive bladder cancer specimens from 55 patients who had undergone neoadjuvant cisplatin + gemcitabine chemotherapy. These samples were categorized into responders and non-responders based on pathological outcomes after radical cystectomy.
  • Human Bladder Cancer Cell Lines: UMUC3, 647V, and 5637 cell lines were used for in vitro experiments. CDDP-resistant sublines were also generated from these cell lines.

Key Insights and Ideas

  • ERβ as a Predictor of Resistance: Higher ERβ expression in tumor samples was significantly associated with a lack of response to cisplatin-based chemotherapy, particularly in female patients. This suggests ERβ could serve as a biomarker for predicting treatment outcomes.
  • ERβ Directly Induces Resistance: In cell line experiments, reducing ERβ levels (knockdown) made cancer cells more sensitive to cisplatin. Conversely, higher ERβ expression correlated with increased resistance.
  • Estrogen's Dual Role: While estrogen (E2) treatment increased cisplatin resistance in ERβ-positive cells, the anti-estrogen drug tamoxifen enhanced sensitivity. This highlights the critical role of ERβ signaling in mediating resistance.
  • Wnt/β-catenin Pathway Involvement: ERβ signaling appears to modulate the Wnt/β-catenin pathway, which is itself implicated in cisplatin resistance. Estrogen treatment further upregulated β-catenin in resistant cells.
  • Therapeutic Potential of ERβ Targeting: The findings strongly suggest that blocking ERβ activity, for example, with anti-estrogen therapies, could be a viable strategy to overcome cisplatin resistance in bladder cancer.

Key Results

  • Clinical Correlation: 71% of non-responders to neoadjuvant chemotherapy showed ERβ positivity, compared to only 38% of responders (P = 0.016). This association was particularly strong in female patients (100% of non-responders vs. 20% of responders, P = 0.048).
  • Cell Line Sensitivity: ERβ knockdown significantly increased cisplatin sensitivity in UMUC3, 647V, and 5637 cell lines. For example, the IC50 for UMUC3-ERβ-shRNA was 2.01 µM compared to 3.14 µM for control shRNA.
  • Tamoxifen and E2 Effects: Tamoxifen treatment reduced cisplatin IC50 values in ERβ-positive cell lines (e.g., from 4.02 µM to 0.91 µM in UMUC3), while E2 increased resistance.
  • CDDP-Resistant Cells: CDDP-resistant sublines exhibited significantly higher ERβ expression compared to their sensitive counterparts.
  • β-catenin Upregulation: CDDP-resistant cells showed increased β-catenin expression, which was further enhanced by E2 treatment.

Limitations and Future Work

The authors acknowledge that while their findings are compelling, further research is needed.

  • Clinical Validation: While the study shows a strong correlation between ERβ expression and resistance in patient samples, larger prospective studies are needed to validate ERβ as a reliable predictive biomarker for clinical decision-making.
  • Mechanism Elucidation: While the study implicates ERβ in modulating the Wnt/β-catenin pathway, the precise molecular interactions and downstream effects require deeper investigation.
  • Combination Therapies: The study explored tamoxifen and celecoxib (a COX-2 inhibitor) separately and in combination with CDDP. Future work could explore optimal dosing and combinations for clinical application, especially considering the potential for synergistic effects.
  • Sex-Specific Differences: The stronger association of ERβ with resistance in female patients warrants further investigation into sex-specific mechanisms of drug resistance.

The authors suggest that targeting ERβ, particularly with anti-estrogen therapies, could be a valuable strategy to enhance the efficacy of cisplatin chemotherapy, especially in patients with ERβ-positive bladder tumors.

Summary updated

Abstract

The efficacy of cisplatin-based chemotherapy in patients with bladder cancer is often limited due to the development of therapeutic resistance. Our recent findings in bladder cancer suggested that activation of prostaglandin receptors (<i>e.g.</i> EP2, EP4) or cyclooxygenase (COX)-2 induced cisplatin resistance. Meanwhile, emerging evidence indicates the involvement of estrogen receptor-β (ERβ) signals in urothelial cancer progression. In this study, we aimed to investigate whether ERβ activity was associated with cisplatin sensitivity in bladder cancer. Immunohistochemistry in muscle-invasive bladder cancer specimens from 55 patients who had subsequently received at least 3 cycles of cisplatin + gemcitabine neoadjuvant chemotherapy showed that ERβ was positive in 38% of responders vs. 71% of non-responders (<i>P</i> = 0.016), including 42% of male responders vs. 65% of male non-responders (<i>P</i> = 0.142) and 20% of female responders vs. 100% of female non-responders (<i>P</i> = 0.048). Then, cisplatin cytotoxicity was compared in human bladder cancer cell lines. Control sublines endogenously expressing ERβ were significantly more resistant to cisplatin treatment at its pharmacological concentrations, compared with ERβ knockdown sublines via short hairpin RNA virus infection. An ER modulator tamoxifen increased sensitivity to cisplatin in ERα-negative/ERβ-positive cell lines, while, in an estrogen-depleted condition, 17β-estradiol reduced it. Additionally, western blot showed considerable elevation in ERβ expression in cisplatin-resistant bladder cancer sublines, compared with respective controls. Moreover, treatment with tamoxifen or a COX-2 inhibitor celecoxib increased cisplatin sensitivity even in resistant cells, while COX-2/EP2/EP4 inhibitor treatment resulted in reduced expression of ERβ. The expression and activity of β-catenin known to involve cisplatin resistance was also up-regulated in cisplatin-resistant cells, which was further induced by 17β-estradiol treatment. The present results suggest that estrogen-mediated ERβ signaling plays an important role in modulating cisplatin sensitivity in bladder cancer cells. Targeting ERβ during chemotherapy may thus be a useful strategy to overcome cisplatin resistance especially in female patients with ERβ-positive bladder cancer.
BibTeX
@inproceedings{goto2020estrogen,
  author = {Takuro Goto and Eiji Kashiwagi and Guiyang Jiang and Yujiro Nagata and Yuki Teramoto and Alexander S. Baras and Shinichi Yamashita and Akihiro Ito and Yoichi Arai and Hiroshi Miyamoto},
  title = {{Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.}},
  booktitle = {PubMed},
  year = {2020},
}
Figure